Global Cord Blood (NYSE:CO) Shares Gap Up to $4.63

Global Cord Blood Co. (NYSE:CO)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $4.63, but opened at $4.78. Global Cord Blood shares last traded at $4.80, with a volume of 1,132 shares traded.

The stock has a market cap of $583.44 million, a price-to-earnings ratio of 7.23 and a beta of 0.40. The business has a 50 day simple moving average of $4.94 and a two-hundred day simple moving average of $5.04.

Global Cord Blood (NYSE:CO) last released its quarterly earnings data on Monday, June 28th. The medical research company reported $0.16 earnings per share (EPS) for the quarter. The business had revenue of $46.14 million during the quarter. Global Cord Blood had a return on equity of 11.81% and a net margin of 42.87%.

Hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Global Cord Blood during the 2nd quarter worth about $152,000. Man Group plc lifted its position in shares of Global Cord Blood by 27.5% during the 2nd quarter. Man Group plc now owns 1,758,071 shares of the medical research company’s stock worth $9,388,000 after purchasing an additional 378,765 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Global Cord Blood by 314.6% during the 2nd quarter. Citadel Advisors LLC now owns 36,594 shares of the medical research company’s stock worth $195,000 after purchasing an additional 27,767 shares during the last quarter. Oasis Management Co Ltd. lifted its position in shares of Global Cord Blood by 19.8% during the 2nd quarter. Oasis Management Co Ltd. now owns 2,184,269 shares of the medical research company’s stock worth $11,664,000 after purchasing an additional 361,238 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Global Cord Blood by 90.1% during the 2nd quarter. Qube Research & Technologies Ltd now owns 179,492 shares of the medical research company’s stock worth $958,000 after purchasing an additional 85,061 shares during the last quarter. Institutional investors and hedge funds own 9.92% of the company’s stock.

About Global Cord Blood (NYSE:CO)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Featured Story: Hang Seng Index (HSI)

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.